U.S. patent application number 17/164231 was filed with the patent office on 2021-05-27 for compositions of bakuchiol and methods of making the same.
This patent application is currently assigned to Unigen, Inc.. The applicant listed for this patent is Unigen, Inc.. Invention is credited to Mei-Feng Hong, Qi Jia.
Application Number | 20210154155 17/164231 |
Document ID | / |
Family ID | 1000005374243 |
Filed Date | 2021-05-27 |
![](/patent/app/20210154155/US20210154155A1-20210527-C00001.png)
![](/patent/app/20210154155/US20210154155A1-20210527-C00002.png)
![](/patent/app/20210154155/US20210154155A1-20210527-C00003.png)
![](/patent/app/20210154155/US20210154155A1-20210527-C00004.png)
![](/patent/app/20210154155/US20210154155A1-20210527-D00001.png)
![](/patent/app/20210154155/US20210154155A1-20210527-D00002.png)
![](/patent/app/20210154155/US20210154155A1-20210527-D00003.png)
![](/patent/app/20210154155/US20210154155A1-20210527-D00004.png)
![](/patent/app/20210154155/US20210154155A1-20210527-D00005.png)
![](/patent/app/20210154155/US20210154155A1-20210527-D00006.png)
United States Patent
Application |
20210154155 |
Kind Code |
A1 |
Jia; Qi ; et al. |
May 27, 2021 |
COMPOSITIONS OF BAKUCHIOL AND METHODS OF MAKING THE SAME
Abstract
The present invention provides compositions of bakuchiol (UP246)
having low levels of impurities, particularly furanocoumarin
impurities. The present invention further provides improved methods
for the isolation, purification and analysis of compositions of
bakuchiol. Finally, the present invention provides methods for
using the purified bakuchiol compositions and formulations thereof
for the prevention and treatment of various diseases and conditions
mediated by cyclooxygenase (COX), lipoxygenase (LOX), minor
inflammatory conditions and various microbial infections. The
methods of this invention are comprised of administering to a host
in need thereof an effective amount of the composition of this
invention together with a pharmaceutically acceptable carrier.
Inventors: |
Jia; Qi; (Olympia, WA)
; Hong; Mei-Feng; (Seattle, WA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Unigen, Inc. |
Tacoma |
WA |
US |
|
|
Assignee: |
Unigen, Inc.
Tacoma
WA
|
Family ID: |
1000005374243 |
Appl. No.: |
17/164231 |
Filed: |
February 1, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14807712 |
Jul 23, 2015 |
10905654 |
|
|
17164231 |
|
|
|
|
13049731 |
Mar 16, 2011 |
|
|
|
14807712 |
|
|
|
|
11382309 |
May 9, 2006 |
|
|
|
13049731 |
|
|
|
|
60679337 |
May 9, 2005 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 36/487 20130101;
Y02A 50/30 20180101; A61K 31/05 20130101; A61K 9/0014 20130101 |
International
Class: |
A61K 31/05 20060101
A61K031/05; A61K 36/487 20060101 A61K036/487; A61K 9/00 20060101
A61K009/00 |
Claims
1-31: (canceled)
32. A composition comprised of bakuchiol, which is substantially
free of furanocoumarin impurities.
33. The composition of claim 32, wherein the bakuchiol is isolated
from a plant.
34. The composition of claim 33, wherein the plant is selected from
the Psoralea genus of plants.
35. The composition of claim 34, wherein the plant is selected from
Psoralea corylifolia L. (Luguminosae) or Psoralea glandulosa L.
(Papilionaceae).
36. The composition of claim 34, wherein the composition is
isolated from a plant part selected from seeds, stems, bark, twigs,
tubers, roots, root bark, young shoots, rhixomes, flowers and other
reproductive organs, leaves and other aerial parts and the whole
plant.
37. The composition of claim 32, wherein the amount of bakuchiol in
the composition is the range of about 27% and 100% by weight.
38. The composition of claim 37, wherein the amount of bakuchiol in
the composition is at least 30%.
39. The composition of claim 32, wherein the furanocoumarins are
selected from psoralen and isopsoralen.
Description
RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Application Ser. No. 60/679,337, filed May 9, 2005, entitled
"Generation of High Purity Bakuchiol as a Therapeutic Agent," which
is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to compositions of bakuchiol
and compounds related thereto having low levels of impurities,
particularly furanocoumarin impurities. The present invention
provides improved methods for the isolation, purification and
analysis of compositions of bakuchiol. Finally, the present
invention provides methods for using the purified bakuchiol
compositions and formulations thereof for the prevention and
treatment of various diseases and conditions mediated by
cyclooxygenase (COX), lipoxygenase (LOX), minor inflammatory
conditions and various microbial infections.
BACKGROUND OF THE INVENTION
[0003] Bakuchiol, the structure of which is illustrated below, is a
phenolic compound having a single hydroxyl group on the aromatic
ring and an unsaturated hydrocarbon chain. It has been isolated
from the seeds of Psoralea, corylifolia L. (Luguminosae) and the
aerial part of Psoralea, glandulosa L. (Papilionaceae),
##STR00001##
[0004] Bakuchiol, extracted from the plant Psoralea corylifolia,
has been shown to have anti-tumor, anti-oxidant (Haraguchi et al.
(September 2002) Phytother Res, 16(61:539-544), cytotoxic
((December, 1989) Yakugaku Zasshi. 109(12):962-965), anti-microbial
(Newton et al. (January 2002) J Ethnopharmacol. 79(11:57-67) and
hepatoprotective activity (Cho et al. (November, 2001) Planta Med,
67(81:750-751). It has also been shown to be a topoisomerase II
inhibitor (Sun et al. (March 1998) J Nat Prod. 61(31:362-366).
Bakuchiol inhibits PTP1B activity in a dose-dependent manner,
displaying IC.sub.50 values of 20.8+/-1.9 .mu.M (Kim et al.
(January 2005) Planta Med. 71(11:87-99). The preparation and in
vitro evaluation of radioiodinated bakuchiol as an anti tumor agent
has been reported by Batap et al ((March, 2005) Appl Radial Isot.
62(31:389-393). The terpenoid chain of bakuchiol has been reported
to be critical to its anti-oxidant activity (Adhikari et al.
(September, 2003) Chem Res Toxicol. 16(91:1062-1069).
[0005] Bakuchiol has also been reported as being a useful compound
for the development of antibacterial agents against oral pathogens
and as having great potential for use in food additives and
mouthwash for preventing and treating dental caries (Katsura et al
(November 2001) Antimicrob Agents Chemother, 45(111:3009-3013). The
anti-inflammatory and antipyretic activity guided fractionation of
the active extracts of Psoralea corylifolia resulted in the
isolation of bakuchiol together with three other active compounds:
cyclobakuchiols A and B and angelicin. (Backhouse et al. (November
2001) J Ethnopharmacol. 78(11:27-31). Bakuchiol reportedly controls
leukocytic functions such as eicosanoid production, migration and
degranulation in the inflammatory site and is a weak inhibitor of
secretary and intracellular PLA2. It dose-dependently reduces the
formation of LTB4 and TXB2 by human neutrophils and platelet
microsomes, respectively (Ferrandiez et al (September 1996) J Pharm
Pharmacol. 48(9):975-980). It also inhibits the expression of the
inducible nitric oxide synthase gene via the inactivation of
nuclear transcription factor-kappaB in RAW 264.7 macrophages. (Pae
et al (September 2001) International Immunopharmacol. 1
(9-101:1849-1855). Inhibition of mitochondrial lipid peroxidation
by bakuchiol has also been reported (Haraguchi et al. (August 2000)
Planta Med. 66(61:569-571). The isolation and antihyperglycemic
activity of bakuchiol isolated from Otholobium pubescens (Fabaceae)
is described by Krenisky et al. in Biol Pharm Bull, (October, 1999)
22(10): 1137-1140). Finally, a crude extract referred to as Buguzhi
agent, containing bakuchiol, as well as, a number of other coumarin
type compounds has been reported as promoting bone healing
(US2004/0043089A1).
[0006] Bakuchiol, therefore, is a biologically active natural
product having a great deal of potential for use in the prevention
and treatment of various diseases and conditions. However, there
are currently a number of limitations associated with the use of
this compound due primarily to its low concentration in natural
sources, as well as the presence of co-existing toxic components.
One of the main problems related to the use of bakuchiol
compositions isolated from plants in the Psoralea genus is the
presence of psoralens, such as psoralen and isopsoralen, the
structures of which are set forth below. Psoralens, also known as
furanocoumarins, are naturally occurring secondary metabolites in
plants, including many fruits and vegetables.
##STR00002##
[0007] A number of health risks have been associated with the
handling, topical application and ingestion of psoralen-containing
plants and synthetic psoralens. Psoralens are well known to be
phototoxic agents, which increase the sensitivity of skin to ultra
violet radiation and promote skin cancer (Epstein (1999) Med, Surg,
18(4):274-284). Psoralen has been shown to induce growth inhibition
in rats (Diawara et al. (1997) Cancer Lett, 114(1-2):159-160).
Gonadal toxicity from crude extracts of Psoralea plants has been
linked directly with the disruption of the
hypothalamus-pituitary-gonadal axis (Takizawa et al. (2002) J.
Toxicological Sciences 27(20:97-105). Oral administration of the
psoralens, bergapten (5-methoxypsoralen) and xanthotoxin
(8-methoxypsoralen) in the diet of female rats reduced birthrates,
the number of implantation sites, pups, corpora lutea, full and
empty uterine weight, and circulating estrogen levels in a
dose-dependent manner (Diawara et al. (1999) J. Biochem, Molecular
Toxicology 13(3/4): 195-203). Psoralens have also been shown to
induce the mRNAs of the liver enzymes CYP1A1 and UGT1A6, suggesting
that enhanced metabolism of estrogens by psoralens may explain the
reproductive toxicity and the observed reduction of ovarian
follicular function and ovulation (Diawara et al. (May-June 2003)
Pediatr Pathol Mol Med, 22(3):247-58.) Psoralen and isopsoralen
account for about 0.1-2% of the dry weight of Psoralea seeds and
about 1-20% of the weight in ethanol and other organic solvent
crude extracts. There remains a need for a method for removing
toxic compounds, such as psoralen and isopsoralen, as well as other
coumarins in order to enhance the purity and safety of bakuchiol
compositions, particularly those isolated from plant sources.
[0008] The release and metabolism of arachidonic acid (AA) from the
cell membrane results in the generation of pro-inflammatory
metabolites by several different pathways. Arguably, two of the
most important pathways to inflammation are mediated by the enzymes
lipoxygenase (LOX) and cyclooxygenase (COX). These are parallel
pathways that result in the generation of leukotrienes and
prostaglandins, respectively, which play important roles in the
initiation and progression of the inflammatory response. These
vasoactive compounds are chemotaxins, which promote infiltration of
inflammatory cells into tissues and serve to prolong the
inflammatory response.
[0009] Inhibition of the COX enzyme is the mechanism of action
attributed to most non-steroidal anti-inflammatory drugs (NSAIDS).
There are two distinct isoforms of the COX enzyme (COX-1 and
COX-2), which share approximately 60% sequence homology, but differ
in expression profiles and function. COX-1 is a constitutive form
of the enzyme, which has been linked to the production of
physiologically important prostaglandins, which help to regulate
normal physiological functions, such as platelet aggregation,
protection of cell function in the stomach and maintenance of
normal kidney function. (Dannhardt and Kiefer (2001) Eur. J. Med.
Chem. 36:109-26). The second isoform, COX-2, is a form of the
enzyme that is inducible by pro-inflammatory cytokines, such as
interleukin-1.beta. (IL-1.beta.) and other growth factors,
(Herschmann (1994) Cancer Metastasis Rev, 134:241-56: Xie et al.
(1992) Drugs Dev. Res. 25:249-65). This isoform catalyzes the
production of prostaglandin E.sub.2 (PGE2) from arachidonic acid
(AA).
[0010] Inhibitors that demonstrate dual specificity for COX and LOX
would have the obvious benefit of inhibiting multiple pathways of
arachidonic acid metabolism. Such inhibitors would block the
inflammatory effects of prostaglandins (PG), as well as, those of
multiple leukotrienes (LT) by limiting their production. This
includes the vasodilation, vasopermeability and chemotactic effects
of PGE2, LTB4, LTD4 and LTE4, also known as the slow reacting
substance of anaphalaxis. Of these, LTB4 has the most potent
chemotactic and chemokinetic effects, (Moore (1985) in Prostanoids:
pharmacological, physiological and clinical relevance. Cambridge
University Press, N.Y., pp. 229-230).
[0011] Because the mechanism of action of COX inhibitors overlaps
that of most conventional NSAID's, COX inhibitors are used to treat
many of the same symptoms, including pain and swelling associated
with inflammation in transient skin conditions and chronic diseases
in which inflammation plays a critical role. Consequently, the
enzymes responsible for generating these mediators of inflammation
have become the targets in the development of a number of novel
drugs aimed at the treatment of inflammation, which contributes to
the pathogenesis of diseases such as rheumatoid arthritis,
osteoarthritis and Alzheimer's disease.
[0012] Transient skin conditions include treatment of inflammation
associated with minor abrasions or contact dermatitis, as well as,
skin conditions that are directly associated with the prostaglandin
and leukotriene pathways, such as skin hyperpigmentation, age
spots, vitilago, systemic lupus erythromatosus, psoriasis,
carcinoma, melanoma, and other mammalian skin cancers. The use of
COX inhibitors has been expanded to include diseases, such as
systemic lupus erythromatosus (SEE) (Goebel et al. (1999) Chem,
Res. Toxicol. 112:488-500; Patrono et al. (1985) J. Clin. Invest.
76:1011-1018), as well as rheumatic skin conditions, such as
scleroderma. COX inhibitors are also used for the relief of
inflammatory skin conditions that are not of rheumatic origin, such
as psoriasis, in which reducing the inflammation resulting from the
overproduction of prostaglandins could provide a direct benefit.
(Fogh et al. (1993) Acta Derm Venerologica 73:191-193). Recently
over expression of 5-lipoxygenase in the skin of patients with
system sclerosis has been reported. This has led to the suggestion
that the LOX pathway may be of significance in the pathogenesis of
system sclerosis and may represent a valid therapeutic target.
(Kowal-Bieleeka (2001) Arthritis Rheum. 44(8): 1865). Finally, the
increased enzymatic activity of both the COX-2 and 5-LOX at the
site of allergen injections suggests the potential for using dual
COX/LOX inhibitors to treat the symptoms of both the early and late
phases of the skin allergic response. (Church (2002) Clin. Exp.
Allergy. 32(7): 1013).
[0013] Prostaglandins and leukotrienes also play important roles in
the physiological and pathological processes of wounds, burns,
scald, acne, microbial infections, dermatitis, and many other
diseases and conditions of the skin. The activation of a
pro-inflammatory cascade after thermal or chemical burns with
significantly elevated cyclooxygenase and lipoxygenase activities
are well documented and play an important role in the development
of subsequent severe symptoms and immune dysfunction that may lead
to multiple organ failure, (Schwacha (2003) Burns 29(11:1: He
(2001) J. Burn Care Rehabil. 22013:58).
[0014] In addition to their use as anti-inflammatory agents,
another potential role for COX inhibitors is in the treatment of
cancer. Over expression of COX has been demonstrated in various
human malignancies and inhibitors of COX have been shown to be
efficacious in the treatment of animals with skin tumors. While the
mechanism of action is not completely understood, the over
expression of COX has been shown to inhibit apoptosis and increase
the invasiveness of tumorgenic cell types. (Dernpke et al, (2001)
J. Can, Res. Clin. Oncol. 127:411-17; Moore and Simmons (2000)
Current Med. Chem, 7:1131-1144). Up regulated COX production has
been implicated in the generation of actinic keratosis and squamous
cell carcinoma in skin. Increased amounts of COX were also found in
lesions produced by DNA damage. (Buckman et al. (1998)
Carcinogenesis 19:723). Therefore, control of expression or protein
function of COX would seem to lead to a decrease in the
inflammatory response and the eventual progression to cancer. In
fact, COX inhibitors such as indomethacin and Celebrex.TM. have
been found to be effective in treating UV induced erythema and
tumor formation. (Fischer (1999) Mol. Carcinog. 25:231: Pentland
(1999) Carcinogenesis 20:1939). Recently, the over expression of
lipoxygenase has also been shown to be related to epidermal tumor
development (Muller (2002) Cancer Res. 62063:4610) and melanoma
carcinogenesis (Winer (2002) Melanoma Res, 12(53:429). The
arachidonic acid (AA) metabolites generated from lipoxygenase
pathways play important roles in tumor growth related signal
transduction suggesting that that the inhibition of lipoxygenase
pathways should be a valid target to prevent cancer progression.
(Cuendet (2000) Drug Metabol Drug Interact 17(4): 109: Steele
(2003) Mutat Res. 523-524:137). Thus, the use of therapeutic agents
having dual COX/LOX inhibitory activity offers significant
advantages in the chemoprevention of cancer.
[0015] Acne is a chronic disease of the pilosebaceous unit
characterized by excess production of sebum by the sebaceous
glands, follicular epithelial desquamation, bacterial proliferation
and inflammation. Hormone imbalance, microbial infection and
inflammation are three of the major factors associated with the
onset of acne (Toombs (2005) Dermatol. Clin. 23(3):575-581;
Nishijima et al, (2000) J. Dermatol, 27(53:318-323). Current
therapeutic agents for the prevention and treatment of acne include
anti-inflammatory agents, such as retinoids, antimicrobial agents
and hormonal drags. (Leyden (2003) J. Am, Acad. Dermatol, 49(3
Suppl):S200).
[0016] The principal bacterial species associated with acne are
Propionibacterium acnes and gram-positive Staphylococcus
epidermidis (Perry and Lambert (2006) Lett. Appl. Microbiol. 42(3):
185-188). Current therapeutic agents include benzoyl peroxide and
other antimicrobial drugs, such as Ampicillin and Gentamicin
(Fermandez et al. (2005) Expert Rev. Anti Infect Ther.
3(4)::557-591). Unfortunately, drug resistance by both
Propionibacterium acnes and Staphylococcus epidermidis has been
reported (Nishijima et al. (2000) J. Dermatol. 27(5):318-323).
[0017] The topical application of anti-inflammatory drags, such as
retinoids (Millikan (2003) J. Am. Acad. Dermatol. 4(2):75) and the
COX inhibitor salicylic acid (Lee (2003) Dermatol Surg 29(12):
1196) have also been clinically demonstrated to be an effective and
safe therapy for the treatment of acne. Additionally, the use of
nonsteroidal anti-inflammatory drugs (NSAIDs) are well documented
as therapeutic agents for common and uncommon dermatoses, including
acne, psoriasis, sun burn, erythema nodosum, cryoglobulinemia,
Sweet's syndrome, systemic mastocytosis, urticarial, liverdoid and
nodular vasculitis. (Friedman (2002) J. Cutan Med. Surg.
6(5):449).
[0018] Periodontal disease is an inflammation and infection of some
or all of the tooth support structures (gingiva, cementum,
periodontal ligament, alveolar bone and other tissues surrounding
the teeth). Gingivitis (gums) and periodontitis (gums and bone) are
the two main forms of periodontal disease. According to National
Oral Information distributed by the National Institute of Dental
and Craniofacial Research, an estimated 80 percent of American
adults currently have some form of periodontal disease. Periodontal
disease is initiated when a pellicle forms on a clean tooth or
teeth. This pellicle attracts aerobic gram-positive bacteria
(mostly actinomyces and streptococci), which adhere to the tooth
forming plaque. Within days the plaque thickens, the underlying
bacteria ran out of oxygen and anaerobic motile rods and
spirochetes begin to populate the subgingival area. Endotoxins
released by the anaerobic bacteria cause inflammation, gum tissue
destruction and even bone loss. There are four primary stages of
periodontal disease that can be characterized as indicated below.
The destructive impact of periodontal disease goes beyond dental
hygiene and health, in that microscopic lesions resulting from
periodontal disease have been found in the liver, kidneys, and
brain of some affected persons.
TABLE-US-00001 Four Stages of Periodontal Disease Grade 1
Inflammation Grade 2 Inflammation, edema, gingival bleeding upon
probing Grade 3 Inflammation, edema, gingival bleeding upon
probing, pustular discharge -- slight to moderate bone loss Grade 4
Inflammation, edema, gingival bleeding upon probing, pustular
discharge, mobility -- severe bone loss
[0019] Current methods for treating periodontal disease are limited
with control of the infection being the primary goal. (Genco et al.
(1990) in Contenporary Periodontics, The C.V. Mosby Company, St.
Louis, pp. 361-370.). Common anti-microbial or anti-plaque agents
include chlorhexidine, Triciosan, stannous fluoride, Listerine,
hydrogen peroxide, cetylpyridimiun chloride and sanguinarine
alkaloids. Prescription anti-microbial mouth rinse-antiseptic chip,
antibiotic gel/micro-spheres, and enzyme suppressant-doxycycline
are the preferred non-meehanical/physieal options to treat and
control periodontal disease. Unfortunately, there is currently no
single periodontal medication which functions to both control the
inflammation as well as inhibit the infection.
[0020] It is to be understood that both the foregoing general
description and the following detailed description are exemplary
and explanatory only and are not restrictive of the invention as
claimed.
SUMMARY OF THE INVENTION
[0021] The present invention includes a novel composition of matter
comprised of bakuchiol, which is substantially free of impurities,
particularly furanocoumarin impurities. This composition of matter
is also referred to herein as IJP256. In some embodiments, the
composition is obtained from the family of plants including, but
not limited to Luguminosae, Papilionaceae, Lauraceae and
Magnoliaceae. In other embodiments, the composition is obtained
from a plant or plants selected from the genus of plants including,
but not limited to Psorlea, Sassafras, Magnolia and Astractylodes.
In preferred embodiments, the plant is selected from the group
including, but not limited to Psoralea corylifolia L. (Luguminosae)
or Psoralea glandulosa L. (Papilionaceae). The composition of the
invention may be obtained from the whole plant or from one or more
individual parts of the plant including, but not limited to the
seeds, stems, bark, twigs, tubers, roots, root bark, young shoots,
rhixomes, flowers and other reproductive organs, leaves and other
aerial parts.
[0022] The amount of bakuchiol in the composition can be in the
range of about 14 to 100 weight percent (%) depending on the method
of extraction and the extent of purification of the crude extract,
in one embodiment the amount of bakuchiol in the composition is in
the range of 30% to 100%. In other embodiments the amount of
bakuchiol in the composition is selected from the group consisting
of at least 30%, at least 35%, at least 40%, at least 45%, at least
50%, at least 60%, at least 70%, at least 80%, or at least 90%. In
a preferred embodiment, the amount of bakuchiol in the composition
is approximately 30%.
[0023] An impurity includes any substance that is unwanted in the
bakuchiol composition. Typically, the impurities present in the
bakuchiol compositions are a result of the process employed to
produce them, including both isolation from natural sources and
synthetic methods. For example, in the isolation of bakuchiol from
natural sources impurities include furanocoumarins, such as
psoralen, isopsoralen and other coumarin type components.
[0024] The present invention also includes improved methods for
isolating and purifying crude compositions of bakuchiol and related
compounds obtained from natural sources. The improved method for
isolating and purifying these compositions includes the steps of
extraction of the compounds from a plant source, hydrolysis of the
crude extract with a basic solution, and purification by a method
including but not limited to column chromatography, extraction
followed by crystallization, solvent partition, recrystallization
and combinations thereof. Crude extracts purified in this manner
are essentially free of furanocoumarin impurities such as psoralen
and isopsoralen. Thus, the potential phototoxicity, topical
irritation, carcenogenecity, and reproductive toxicity associated
with these compounds are essentially eliminated. The purity of
these compositions following isolation and purification by the
methods of the instant invention is in a range selected from about
27% to 100%.
[0025] Also included in the present invention is a method for
analyzing compositions of bakuchiol, which enables detection and
quantification of impurities. In this embodiment of the invention,
the method for analyzing compositions of bakuchiol is comprised of
the step of analyzing said compositions by high-pressure liquid
chromatography (HPLC). Analysis by HPLC enables quantification of
the various components in the mixture and also provides a means to
track bakuchiol, psoralen, isopsoralen and other natural components
in Psoralea plants to guide the extraction, hydrolysis and
purification processes.
[0026] The present invention also includes methods for the
prevention and treatment of COX and LOX mediated diseases and
conditions of the skin, mouth, teeth and gums. The method for
preventing and treating COX and LOX mediated diseases and
conditions of the skin, mouth, teeth and gums is comprised of
administering, preferably topically, to a host in need thereof an
effective amount of a composition comprising bakuchiol, which is
substantially free of furanocumarin impurities together with a
pharmaceutically acceptable carrier. As noted above, the amount of
bakuchiol in the composition is in the range of 27% to 100%, In
preferred embodiments the amount of bakuchiol in the composition is
approximately 30%, Also as noted above, in preferred embodiments,
the bakuchiol is isolated from a plant or plants in the Psorlea
genus of plants.
[0027] COX and LOX mediated diseases or conditions of the skin
include, but are not limited to, acne, dandruff, sun burn, thermal
burns, topical wounds, minor inflammatory conditions caused by
fungal, microbial and viral infections, vitilago, systemic lupus
erytbromatosus, psoriasis, carcinoma, melanoma, as well as other
mammal skin cancers, skin damage resulting from exposure to
ultraviolet (UV) radiation, chemicals, heat, wind and dry
environments, wrinkles, saggy skin, lines and dark circles around
the eyes, dermatitis and other allergy related conditions of the
skin. CQX/LOX mediated diseases and conditions of the mouth, teeth
and gums, include, but not limited to periodontal diseases, oral
pre-cancerous conditions, oral cancers, and other oral
malignancies, sensitive gums and teeth, sequelae, pulpitis,
irritation, pain and inflammation caused by the physical
implantation of oral dentures, trauma, injuries, bruxism and other
minor wounds in mouth, on the gums or on the tongue, dental plague
and calculus, tooth decalcification, proteolysis and caries
(decay).
[0028] The present invention further includes methods for the
prevention and treatment of other COX and LOX mediated diseases and
conditions, including but not limited to general joint pain and
stiffness, lack of mobility and loss of physical function due to
pathological conditions of osteoarthritis and rheumatoid arthritis,
menstrual cramps, arteriosclerosis, obesity, diabetes, Alzheimer's
disease, respiratory allergic reaction, chronic venous
insufficiency, psoriasis, chronic tension headache, migraine
headaches, inflammatory bowl disease, prostate cancer and other
solid tumors.
[0029] The method for preventing and treating said COX and LOX
mediated diseases and conditions is comprised of administering to a
host in need thereof an effective amount of a composition
comprising bakuchiol, which is substantially free of furanocumarin
impurities together with a pharmaceutically acceptable carrier. As
noted above, the amount of bakuchiol in the composition is in the
range of 21% to 100%. In preferred embodiments the amount of
bakuchiol in the composition is approximately 30%. Also as noted
above, in preferred-embodiments, the bakuchiol is isolated from a
plant or plants in the Psorlea genus of plants.
[0030] Further included in the present invention are methods for
the prevention and treatment of diseases and conditions of the
skin, mouth, teeth or gums mediated by microbial infections,
including but not limited to bacterial, viral and fungal
infections, said method comprising administering to a host in need
thereof an effective amount of a pharmaceutical composition
comprised of bakuchiol, which is substantially free of
furanocoumarin impurities together with a pharmaceutically
acceptable carrier. Diseases and conditions of the skin, mouth,
gums and teeth mediated by microbial infections include, but are
not limited to dandruff, acne, athletes foot, periodontal diseases,
selected from the group consisting of caries, gingivitis,
periodontitis, pulpitis, periodontal conditions caused by the
physical implantation of oral dentures, trauma, injuries, bruxism,
neoplastic and other degenerative processes; material alba,
pellicles, dental plagues, calculus and stains.
[0031] In one embodiment, the bacterium is selected from
Propionibacterium acnes or Staphylococcus epidermidis.
[0032] The compositions of this invention can be administered by
any method known to one of ordinary skill in the art. The modes of
administration include, but are not limited to, enteral (oral)
administration, parenteral (intravenous, subcutaneous, and
intramuscular) administration and topical application. In preferred
embodiments the compositions are administered topically. The method
of prevention and treatment according to this invention comprises
administering internally or topically to a patient in need thereof
a therapeutically effective amount a composition comprised of
bakuchiol, which is substantially free of impurities, particularly
furanocoumarin impurities.
[0033] It is to be understood that both the foregoing general
description and the following detailed description are exemplary
and explanatory only and are not restrictive of the invention as
claimed.
BRIEF DESCRIPTION OF THE DRAWINGS
[0034] FIG. 1 illustrates the HPLC chromatogram of a representative
extract from Psoralea plants. Two furanocoumarins--psoralen and
isopsoralen are present in an equal amount in the extract.
[0035] FIG. 2 illustrate the HPLC chromatograms of Psoralea
extracts before (FIG. 2A) and after (FIG. 2B) sodium hydroxide
hydrolysis reaction.
[0036] FIG. 3 depicts the HPLC chromatogram of a UP256 sample
(MH-258-07-01) comprised of 31% bakuchiol.
[0037] FIG. 4 depicts the HPLC chromatogram of a UP256 sample
(MH-258-07-02) comprised of 41% bakuchiol.
[0038] FIG. 5 depicts the HPLC chromatogram of a UP256 sample
(MH-258-12-08) comprised of 99% bakuchiol.
[0039] FIG. 6 depicts graphically a dose response curve of the
inhibition of the activity of the enzyme 5-lipoxygenase (5-LO) by a
UP256 composition (#MH-258-12-08-.circle-solid.-) relative to
positive control--NDGA (-.box-solid.-).
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
[0040] The present invention includes compositions of bakuchiol
(UP246) having low levels of impurities. Included in the present
invention are improved methods for the isolation and purification
of compositions of bakuchiol. Also included in the present
invention is a method for analyzing compositions of bakuchiol,
which enables the detection and quantification of various
impurities. Further included in this invention is a method for
using the purified bakuchiol compositions and formulations thereof
for the prevention and treatment of various diseases and conditions
mediated by cyclooxygenase (COX), lipoxygenase (LOX), minor
inflammatory conditions and various microbial infections.
[0041] Various terms are used herein to refer to aspects of the
present invention. To aid in the clarification of the description
of the components of this invention, the following definitions are
provided.
[0042] It is to be noted that the term "a" or "an" entity refers to
one or more of that entity. As such, the terms "a" or "an", "one or
more" and "at least one" are used interchangeably herein.
[0043] "Bakuchiol" as used herein refers to the compound having the
following formula:
##STR00003##
wherein the central double-bond may be either cis or trans.
Phenolic compounds structurally related to bakuchiol are also
included within this definition.
[0044] As used herein the term "impurity" includes any substance
that is not wanted in the bakuchiol composition, typically
resulting from the isolation of bakuchiol from natural sources. The
term impurity includes, but is not limited to furanocoumarin
compounds selected from the group including but not limited to
psoralen, isopsoralen and other coumarin type impurities.
Impurities also refer to impurities resulting from synthetic
processes to obtain these compositions.
[0045] "Therapeutic" as used herein, includes treatment and/or
prophylaxis. When used, therapeutic refers to humans as well as
other animals.
[0046] "Pharmaceutically or therapeutically effective dose or
amount" refers to a dosage level sufficient to induce a desired
biological result. That result may be the alleviation of the signs,
symptoms or causes of a disease or any other alteration of a
biological system that is desired.
[0047] "Placebo" refers to the substitution of the pharmaceutically
or therapeutically effective dose or amount dose sufficient to
induce a desired biological that may alleviate the signs, symptoms
or causes of a disease with a non-active substance.
[0048] A "host" or "patient" is a living subject, human or animal,
into which the compositions described herein are administered.
Thus, the invention described herein may be used for veterinary as
well as human applications and the terms "patient" or "host" should
not be construed in a limiting manner. In the case of veterinary
applications, the dosage ranges can be determined as described
below, taking into account the body weight of the animal.
[0049] Note that throughout this application various citations are
provided. Each citation is specifically incorporated herein by
reference in its entirety.
[0050] The present invention includes a novel composition of matter
comprised of bakuchiol, which is substantially free of impurities,
particularly furanocoumarin impurities. This composition of matter
is also referred to herein as UP256. In some embodiments, the
composition is obtained from a plant or plants selected from the
Psorlea genus of plants. In preferred embodiments the plant is
selected from the group including, but not limited to Psoralea
corylifolia L. (Luguminosae) or Psoralea glandulosa L.
(Papilionaceae). The composition of the invention may be obtained
from the whole plant or from one or more individual parts of the
plant including, but not limited to the seeds, stems, bark, twigs,
tubers, roots, root bark, young shoots, rhixomes, flowers and other
reproductive organs, leaves and other aerial parts.
[0051] The amount of bakuchiol in the composition can be in the
range of about 14 to 100 weight percent (%) depending on the method
of extraction and the extent of purification of the crude extract,
in one embodiment the amount of bakuchiol in the composition is in
the range of 30% to 100%. In other embodiments the amount of
bakuchiol in the composition is selected from the group consisting
of at least 30%, at least 35%, at least 40%, at least 45%, at least
50%, at least 60%, at least 70%, at least 80%, or at least 90%. In
a preferred embodiment, the amount of bakuchiol in the composition
is approximately 30%.
[0052] An impurity includes any substance that is unwanted in the
bakuchiol composition. Typically, the impurities present, in the
bakuchiol compositions are a result of the process employed to
produce them, including both isolation from natural sources and
synthetic methods. For example, in the isolation of bakuchiol from
natural sources impurities include furanocoumarins, such as
psoralen, isopsoralen and other coumarin type components.
[0053] The present invention also includes improved methods for
isolating, analyzing and purifying crude compositions of bakuchiol
obtained from natural sources. The improved method for isolating
and purifying these compositions includes the steps of extraction
of the compound from a plant source, hydrolysis of the crude
extract with a basic solution, and purification by a method
including but not limited to column chromatography, extraction
followed by crystallization, solvent partition, recrystallization
and combinations thereof. Crude extracts purified in this manner
are essentially free of furanocoumarin impurities such as psoralen
and isopsoralen.
[0054] A method for analyzing compositions of bakuchiol using high
pressure liquid chromatography (HPLC) is described in Example 1
(Table 1). Analysis by HPLC enables quantification of the various
components in the mixture and also provides a means to track
bakuchiol, psoralen, isopsoralen and other natural components in
Psoralea plants to guide the extraction, hydrolysis and
purification processes.
[0055] The efficiency of bakuchiol extraction from plant sources
was evaluated using six different organic solvent systems under two
sets of extraction conditions as described in Example 2. The
results are set forth in Table 2. With reference to Table 2, it can
be seen that bakuchiol can be extracted from Psoralea plants with
any number of organic solvents and/or combinations thereof. The
amount of bakuchiol in the various extracts ranged from a maximum
of 29.1% to 13.7% by weight. It was determined that extraction with
petroleum ether provided the highest purity bakuchiol in the crude
extract with good recovery. A representative HPLC chromatogram of a
crude extract is illustrated in FIG. 1. With reference to this
figure it can be seen that the crude extract contained bakuchiol as
well as the furanocoumarin impurities psoralen and isopsoralen.
Example 3 describes a large scale extraction with petroleum ether
at 70.degree. C.
[0056] The efficacy of purification of crude bakuchiol extracts by
column chromatography is demonstrated in Example 4. Eight different
types of resins were evaluated specifically for their ability to
separate bakuchiol from furanocoumarin impurities. Both silica gel
and CG-161 resins demonstrated satisfactory separation. Column
chromatographic separation of crude plant extracts on an industrial
scale, however, is typically not economically feasible in that it
requires expensive equipment and reagents and experienced
personnel, not to mention the extremely low loading capacity of
these samples due to the complexity of crude plant extracts.
[0057] Examples 5-7 describe a novel, economical method for
separating bakuchiol from furanocoumarin impurities, said method
comprising treatment of compositions containing said impurities
with a base. As illustrated by the following scheme, using NaOH for
purposes of illustration, treatment with base opens up the lactone
ring of the furanocournarins, thereby-converting them into the
corresponding salts of carboxylic acids, which can then be easily
separated from the remainder of the mixture by a variety of
methods.
##STR00004##
[0058] The basic solution can be selected from any base which can
be used to open lactone rings, including, but not limited to sodium
hydroxide, potassium hydroxide, calcium hydroxide and lithium
hydroxide. The solution can be selected to have different
concentration and pH values to maximize the conversion to the acid
salt. The reaction mixture can also be heated under different
temperature and pressures to maximize the reaction rate, efficiency
and yield.
[0059] The course of the reaction can be followed by HPLC to ensure
complete conversion of the coumarins into their respective
carboxylic acid salts. The HPLC chromatograms of the crude
composition before and after hydrolysis are illustrated in FIGS. 2A
and B. Upon completion of the reaction (as determined by HPLC), the
reaction solution can be processed using various methods, including
but are not limited to column chromatography extraction followed by
crystallization, solvent partition, recrystallization or
combinations thereof. Grude extracts purified in this manner are
essentially free of furanocoumarin impurities such as psoralen and
isopsoralen.
[0060] With reference to Examples 5-7, upon hydrolysis under a
variety of conditions followed by solvent partition, the
furanocoumarins, psoralen and isopsoralen, are effectively removed
from the bakuchiol composition. Additionally, the purity of
bakuchiol is enhanced from about 10-30% to 30%-50%. Organic
solvents that can be used for solvent partition include, but are
not limited to petroleum ether, ethyl acetate, ethyl ether, hexane,
chloroform, propanol, butanol, and methylene chloride, as well as
other water immiscible organic solvents.
[0061] In one embodiment, which is described in Example 7, the
crude reaction mixture is loaded directly onto a column followed by
elution with a polar solvent. According to this embodiment
compositions comprised of 70% to 100% of bakuchiol can be obtained.
In Example 7, following hydrolysis the crude reaction mixture was
loaded directly onto a CG-161 cd column followed by elution with
methanol to provide highly pure (approximately 99%) bakuchiol.
Other types of resins that can be used according to this embodiment
include, but are not limited to XAD (Ameriite), CG-71/CG-161 or
other type of polystyrene resins; ion exchange resins and silica
gel. The column can be eluted with solvents selected from the group
including, but not limited to water, methanol/water, ethanol/water,
acetone/water and acetonitrile/water as well as other combinations
of polar solvents. It is worth noting that the loading capacity of
the column after hydrolysis was much higher than prior to
hydrolysis. Additionally, the color of these highly pure
furanocoumarin free, bakuchiol compositions was light brown and
they were very stable with respect to both color and composition of
the active agent, making them particularly suitable for
formulation, storage and cosmetic applications.
[0062] In alternate embodiments, the crude reaction mixture can
first be extracted with an organic solvent followed by further
purification by chromatography and/or solvent partition and/or
recrystallization. As noted above, depending on the method of
extraction and extent of further purification bakuchiol
compositions comprised of between about 30% and 100% are readily
obtainable.
[0063] The present invention includes methods for using the
purified bakuchiol compositions and formulations thereof for the
prevention and treatment of various diseases and conditions
mediated by cyclooxygenase (COX), lipoxygenase (LOX), minor
inflammatory conditions and various microbial infections. The
biological properties and safety of these unique furanocoumarin
free bakuchiol compositions, referred to herein as UP256, were
evaluated as described in Examples 8-11.
[0064] In Example 8, a highly pure composition of UP256
(MH-258-12-08, 99% purity) was tested for inhibition of both the
COX-1 and COX-2 enzymes. UP256 showed potent inhibitory activity
for both enzymes. The IC.sub.50 for COX-1 was determined to be 2.34
.mu.M, while IC.sub.50 for COX-2 was quantified at 78 .mu.M. Thus,
this composition provides a more balanced modulation of the COX-1
and COX-2 enzymes than conventional COX inhibitors. For example,
aspirin, a COX-1 selective inhibitor, which is more than 150 times
more effective against COX-1 versus COX-2, causes gastrointestinal
side effects. Conversely, Vioxx.RTM., Celebrex.RTM. and
Rextra.RTM., which are selective COX-2 inhibitors having 50-200
times more potency against COX-2, do not cause as much
gastrointestinal damage, however, these COX-2 selective drugs
increase cardiovascular risks. The novel composition of matter
disclosed herein on the other hand provide the best modulation of
the eieosanoid pathway without the stomach irritation caused by
COX-1 selective NSAIDs and cardiovascular risks posed by COX-2
selective inhibitors.
[0065] It is also significant that the mechanism of action for COX
inhibition by UP256 is completely different than that of NSAIDs.
Aspirin, Vioxx.RTM., Celebrex.RTM. and Bextra.RTM. irreversibly
bind to the COX enzyme through covalent bonds to form tightly bound
enzyme-inhibitor complexes. This interaction completely changes the
active site of the enzyme and the side pocket and destroys the
enzyme. (Walker and Kurumbal et al. (2001) Biochem. 357:709-718).
UP256, on the other hand, inhibits the COX enzyme through a weaker
and reversible binding. In this interactive process, the structure
and function of the COX enzyme are not irreversibly altered which
results in a much better tolerance and safety profile.
[0066] Example 9 describes a LOX inhibition assay. The inhibition
of LOX results in a decrease in the accumulation of phagocytic
leukotrienes, which are directly associated with the symptoms of
chronic inflammation, and also reduces potential gastrointestinal
side effects. Such efficacy is demonstrated in Example 9. With
reference to Example 9, the highly pure UP256 composition,
MH-258-12-08 (99% purity) was tested in duplicate at four
concentrations against the human 5-lipoxygenase (5-LO or 5-LOX)
enzyme. The COX-2 inhibitory activity was confirmed by measurement
of dose response and IC.sub.50 (the concentration required to
inhibit 50% of the enzyme's activity). The dose response curve is
depicted in FIG. 6. The IC.sub.50 for LOX inhibition was determined
to be 3.41 .mu.M. Thus, UP256 provides the additional benefit of
significantly reducing leukotriene production. This reduction in
leukotriene production is by far superior to traditional
non-steroidal anti-inflammatory drugs such as ibuprofen.
[0067] Example 10 describes an experiment designed to determine the
anti-microbial activity UP256. With reference to Example 10, UP256
was tested in duplicate at eight-concentrations for the inhibition
of six different microbes. It was found that UP256 inhibited two
specific microbes, Propionibacterium acnes and gram-positive
Staphylococcus epidermidis, at a minimum effective concentration of
1 .mu.g/mL. Both of these microbes are directly associated with
acne, dermatitis, and other skin infections. UP256 also showed
moderate inhibition of Trichophyton mentagrophytes at a
concentration 30 .mu.g/mL. No inhibition was observed for
Epidermophyton floccosum, Microsporum canis or Pityrosporum
ovale.
[0068] UP256, at concentrations of 30% and 70%, was tested for
acute toxicity in mice as described in Example 10. The mice tested
were given an oral daily of 2 g/kg for 14 days. Mice showed no
adverse effects in terms of weight gain and blood chemistry.
Additionally, no toxicity was observed in any of the major organs
tested. In conclusion, weight, blood work and histological data,
was no different for the treatment group than for the control
group. No adverse effects were observed in the fourteen-day study.
Thus, it can be concluded that UP256 has a solid safety
profile.
[0069] Finally, UP256 has a partition coefficient of log P=6.13.
The partition coefficient of a chemical compound provides a
thermodynamic measure of its hydrophilicity/lipophilicity balance
and thus its potential bioavailability. Having a partition
coefficient of 6.13 means this compound has high cell membrane
penetration and bioavailability when formulated in a delivery
system.
[0070] The present invention therefore includes methods for the
prevention and treatment of COX and LOX mediated diseases and
conditions of the skin, mouth, teeth and gums. The method for
preventing and treating COX and LOX mediated diseases and
conditions of the skin, mouth, teeth and gums is comprised of
administering, preferably topically, to a host in need thereof an
effective amount of a composition comprising bakuchiol, which is
substantially free of furanocumarin impurities together with a
pharmaceutically acceptable carrier. As noted above, the amount of
bakuchiol in the composition is in the range of 27% to 100%. In
preferred embodiments the amount of bakuchiol in the composition is
approximately 30%, Also as noted above, in preferred embodiments,
the bakuchiol is isolated from a plant or plants in the Psorlea
genus of plants.
[0071] COX and LOX mediated diseases or conditions of the skin
include, but are not limited to, acne, dandruff, sun burn, thermal
burns, topical wounds, minor inflammatory conditions caused by
fungal, microbial and viral infections, vitilago, systemic lupus
erythromatosus, psoriasis, carcinoma, melanoma, as well as other
mammal skin cancers, skin damage resulting from exposure to
ultraviolet (UV) radiation, chemicals, heat, wind and dry
environments, wrinkles, saggy skin, lines and dark circles around
the eyes, dermatitis and other allerey related conditions of the
skin. CQX/LOX mediated diseases and conditions of the mouth, teeth
and gums, include, but not limited to periodontal diseases, oral
pre-cancerous conditions, oral cancers, and other oral
malignancies, sensitive gums and teeth, sequelae, pulpitis,
irritation, pain and inflammation caused by the physical
implantation of oral dentures, trauma, injuries, bruxism and other
minor wounds in mouth, on the gums or on the tongue, dental plague
and calculus, tooth decalcification, proteolysis and caries
(decay).
[0072] The present invention further includes methods for the
prevention and treatment of other COX and LOX mediated diseases and
conditions, including but not limited to general joint pain and
stiffness, lack of mobility and loss of physical function due to
pathological conditions of osteoarthritis and rheumatoid arthritis,
menstrual cramps, arteriosclerosis, obesity, diabetes, Alzheimer's
disease, respiratory allergic reaction, chronic venous
insufficiency, psoriasis, chronic tension headache, migraine
headaches, inflammatory bowl disease, prostate cancer and other
solid tumors.
[0073] The method for preventing and treating said COX and LOX
mediated diseases and conditions is comprised of administering to a
host in need thereof an effective amount of a composition
comprising bakuchiol, which is substantially free of furanocumarin
impurities together with a pharmaceutically acceptable carrier. As
noted above, the amount of bakuchiol in the composition is in the
range of 27% to 100%. In preferred embodiments the amount of
bakuchiol in the composition is approximately 30%. Also as noted
above, in preferred embodiments, the bakuchiol is isolated from a
plant or plants in the Psorlea genus of plants.
[0074] Further included in the present invention are methods for
the prevention and treatment of diseases and conditions of the
skin, mouth, teeth or gums mediated by microbial infections,
including but not limited to bacterial, viral and fungal
infections, said method comprising administering to a host in need
thereof an effective amount of a pharmaceutical composition
comprised of bakuchiol, which is substantially free of
furanocoumarin impurities together with a pharmaceutically
acceptable carrier. Diseases and conditions of the skin, mouth,
gums and teeth mediated by microbial infections include, but are
not limited to dandruff, acne, athletes foot, periodontal diseases,
selected from the group consisting of caries, gingivitis,
periodontitis, pulpitis, periodontal conditions caused by the
physical implantation of oral dentures, trauma, injuries, bruxism,
neoplastic and other degenerative processes; material alba,
pellicles, dental plagues, calculus and stains.
[0075] In one embodiment, the bacterium is selected from
Propionibacterium acnes or Staphylococcus epidermidis.
[0076] The compositions of this invention can be administered by
any method known to one of ordinary skill in the art. The modes of
administration include, but are not limited to, enteral (oral)
administration, parenteral (intravenous, subcutaneous, and
intramuscular) administration and topical application. In preferred
embodiments the compositions are administered topically. The method
of prevention and treatment according to this invention comprises
administering internally or topically to a patient in need thereof
a therapeutically effective amount a composition comprised of
bakuchiol, which is substantially free of impurities, particularly
furanocoumarin impurities.
[0077] The method of prevention and treatment according to this
invention comprises administering systemically or topically to a
host in need thereof a therapeutically effective amount of UP256
(bakuchiol) synthesized and/or isolated from a single plant or
multiple plants and a pharmaceutically acceptable carrier. The
purity of the UP256 includes, but is not limited to 30% to 100%,
depending on the methodology used to obtain and purify the
compound. In a preferred embodiment, doses of UP256 an efficacious,
nontoxic quantity generally selected from the range of 0.001% to
100% based on total weight of the topical formulation and/or
0.001-200 mg per kilogram based on the total body weight of the
host. Persons skilled in the art using routine clinical testing are
able to determine optimum doses for the particular ailment being
treated.
[0078] The present invention includes an evaluation of different
compositions of UP256 (bakuchiol) synthesized and/or isolated from
a single plant or multiple plants and a pharmaceutically acceptable
carrier using enzyme, receptor, microbial and other in vitro and in
vivo models to optimize the formulation and obtain the desired
physiological activity. The compositions of this invention can be
administered by any method known to one of ordinary skill in the
art. The modes of administration include, but are not limited to,
enteral (oral) administration, parenteral (intravenous,
subcutaneous, and intramuscular) administration and topical
application. The method of treatment according to this invention
comprises administering internally or topically to a patient in
need thereof a therapeutically effective amount of UP256
(bakuchiol) synthesized and/or isolated from a single plant or
multiple plants, wherein said bakuchiol is substantially free of
furanocoumarin impurities. In a one embodiment the composition is
administered topically. Methods for topical administration include,
but are not limited to a toothpaste, gel, ointment, mouthwash,
chewing gum, tinctures, drinks and as well as other known
pharmaceutical formulations. When formulated in a toothpaste, the
content of the composition can be in the range of 0.1 to 2 weight
percent (%) of bakuchiol.
[0079] The compositions of the present invention can be formulated
as pharmaceutical compositions, which include other components such
as a pharmaceutically and/or cosmetically acceptable excipient, an
adjuvant, and/or a carrier. For example, compositions of the
present invention can be formulated in an excipient that the host
to be treated can tolerate. An excipient is an inert substance used
as a diluent or vehicle for a drug. Examples of such excipients
include, but are not limited to water, buffers, saline, glycerin,
hydrated silica, propylene glycol, aluminum oxide, carrageenan,
cellulose gum, titanium dioxide, Ringer's solution, dextrose
solution, mannitol, Hank's solution, preservatives and other
aqueous physiologically balanced salt solutions. Nonaqueous
vehicles, such as fixed oils, sesame oil, ethyl oleate, or
triglycerides may also be used. Other useful formulations include
suspensions containing viscosity enhancing agents, such as sodium
carboxymethylcellulose, sorbitol, or dextran. Excipients can also
contain minor amounts of additives, such as EDTA, disodium DDTA,
BHA, BHT, diammonium citrate, nordihydroguaiaretic acid, propyl
gallate, sodium gluconate, Sodium metabisulfite, t-butyl
hydroquinone, SnCl.sub.2, H.sub.2O.sub.2, and
2,4,5-trihydroxybutyrophenone, vitamin C vitamin E and other
substances that enhance isotonicity and chemical stability.
Examples of substances for adjusting pH of the formulation include
sodium hydroxide, sodium carbonate, sodium bicarbonate, pentasodium
triphosphate, tetrasodium pyrophosphate, sodium lauryl sulfate,
calcium peroxide, phosphate buffer, bicarbonate buffer, iris
buffer, histidine, citrate, and glycine, or mixtures thereof, while
examples of flavors include, but are not limited to thimerosal, m-
or o-cresol, formalin, fruit extracts and benzyl alcohol. Standard
formulations can either be liquid or solids, which can be taken up
in a suitable liquid as a suspension or solution for
administration. Thus, in a non-liquid formulation, the excipient
can comprise dextrose, human serum albumin, preservatives, etc., to
which sterile water or saline can be added prior to
administration.
[0080] In one embodiment of the present invention, the composition
can also include an adjuvant or a carrier. Adjuvants are typically
substances that generally enhance the biological response of a
mammal to a specific bioactive agent. Suitable adjuvants include,
but are not limited to, Freund's adjuvant; other bacterial cell
wall components; aluminum, calcium, copper, iron, zinc, magnesium,
stannous based salts; silica; polynucleotides; toxoids; serum
proteins; viral coat proteins; other bacterial-derived
preparations; gamma interferon; block copolymer adjuvants, such as
Hunter's Titermax adjuvant (Vaxcel.TM., Inc. Norcross, Ga.); Ribi
adjuvants (available from Ribi ImmunoChem Research, Inc., Hamilton,
Mont.); and saponins and their derivatives, such as Quil A
(available from Superfos Biosector A/S, Denmark). Carriers are
typically compounds that increase the half-life of a therapeutic
composition in the treated host. Suitable carriers include, but are
not limited to, polymeric controlled release formulations,
biodegradable implants, liposomes, bacteria, viruses, oils, esters,
and glycols.
[0081] In one embodiment, the composition is prepared as a
controlled release formulation, which slowly releases the
composition of the present invention into the host. As used herein,
a controlled release formulation comprises a composition of the
present invention in a controlled release vehicle. Suitable
controlled release vehicles will be known to those skilled in the
art. Preferred controlled release formulations are biodegradable
(i.e., bioerodible).
[0082] The therapeutic agents of the instant invention are
administered topically by any suitable means, known to those of
skill in the art for topically administering therapeutic
compositions including, but not limited to as an ointment, gel,
lotion, or cream base or as an emulsion, as a patch, dressing or
mask, a nonsticking gauze, a bandage, a swab or a cloth wipe. Such
topical application can be locally administered to any affected
area, using any standard means known for topical administration. A
therapeutic composition can be administered in a variety of unit
dosage forms depending upon the method of administration. For
particular modes of delivery, a therapeutic composition of the
present invention can be formulated in an excipient of the present
invention. A therapeutic reagent of the present invention can be
administered to any host, preferably to mammals, and more
preferably to humans. The particular mode of administration will
depend on the condition to be treated.
[0083] In one embodiment, a suitable ointment is comprised of the
desired concentration of UP256 (bakuchiol) that is an efficacious,
nontoxic quantity generally selected from the range of 0.001% to
100% based on total weight of the topical formulation, from 65% to
100% (preferably 75% to 96%) of white soft paraffin, from 0% to 15%
of liquid paraffin, and from 0% to 7% (preferably 3 to 7%) of
lanolin or a derivative of synthetic equivalent thereof. In another
embodiment the ointment may comprise a polyethylene--liquid
paraffin matrix.
[0084] In one embodiment, a suitable cream is comprised of an
emulsifying system together with the desired concentration of UP256
(bakuchiol) synthesized and/or isolated from a single plant or
multiple plants as provided above. The emulsifying system is
preferably comprised of from 2 to 10% of polyoxyethylene alcohols
(e.g. the mixture available under the trademark Cetomacrogol.TM.
1000), from 10 to 25% of stearyl alcohol, from 20 to 60% of liquid
paraffin, and from 10 to 65% of water; together with one or more
preservatives, for example from 0.1 to 1% of
N,N''-methylenebis[N'-[3-(hydroxymethyl)-2,5-dioxo-4-imidazolidinyl]urea]-
(available under the name Imidurea USNF), from 0.1 to 1% of alkyl
4-hydroxybenzoates (for example the mixture available from Nipa
Laboratories under the trade mark Nipastat), from 0.01 to 0.1% of
sodium butyl 4-hydroxybenzoate (available from Nipa Laboratories
under the trade mark Nipabutyl sodium), and from 0.1 to 2% of
phenoxyethanol.
[0085] In one embodiment, a suitable gel is comprised of a
semi-solid system in which a liquid phase is constrained within a
three dimensional polymeric matrix with a high degree of
cross-linking. The liquid phase may be comprised of water, together
with the desired amount of UP256 (bakuchiol), from 0 to 20% of
water-miscible additives, for example glycerol, polyethylene
glycol, or propylene glycol, and from 0.1 to 10%, preferably from
0.5 to 2%, of a thickening agent, which may be a natural product,
for example tragacanth, pectin, carrageen, agar and alginic acid,
or a synthetic or semi-synthetic compound, for example
methylcellulose and carboxypolymethylene (carbopol); together with
one or more preservatives, for example from 0.1 to 2% of methyl
4-hydroxybenzoate (methyl paraben) or phenoxyethanol-differential.
Another suitable base, is comprised of the desired amount of UP256
(bakuchiol), together with from 70 to 90% of polyethylene glycol
(for example, polyethylene glycol ointment containing 40% of
polyethylene glycol 3350 and 60% of polyethylene glycol 400,
prepared in accordance with the U.S. National Formulary (USNF)),
from 5 to 20% of water, from 0.02 to 0.25% of an anti-oxidant (for
example butylated hydroxytoluene), and from 0.005 to 0.1% of a
chelating agent (for example ethyienediamine tetraacetic acid
(EDTA)).
[0086] The term soft paraffin as used above encompasses the cream
or ointment bases white soft paraffin and yellow soft paraffin. The
term lanolin encompasses native wool fat and purified wool fat.
Derivatives of lanolin include in particular lanolins which have
been chemically modified in order to alter their physical or
chemical properties and synthetic equivalents of lanolin include in
particular synthetic or semisynthetic compounds and mixtures which
are known and used in the pharmaceutical and cosmetic arts as
alternatives to lanolin and may, for example, be referred to as
lanolin substitutes.
[0087] One suitable synthetic equivalent of lanolin that may be
used is the material available under the trademark Softisan.TM.
known as Softisan 649. Softisan 649, available from Dynamit Nobel
Aktiengesellschaft, is a glycerine ester of natural vegetable fatty
acids, of isostearic acid and of adipic acid; its properties are
discussed by H. Hermsdorf in Fette, Seifen, Anstrichmittel, Issue
No. 84, No. 3 (1982), pp. 3-6.
[0088] The other substances mentioned hereinabove as constituents
of suitable ointment or cream bases and their properties are
discussed in standard reference works, for example pharmacopoeia.
Cetomacrogol 1000 has the formula
CH.sub.3(CH.sub.2)m(OCH.sub.2CH2).sub.nOH, wherein m may be 15 or
17 and n may be 20 to 24. Butyl a ted hydroxytoluene is
2,6-di-tert-butyl-p-cresol. Nipastat is a mixture of methyl, ethyl,
propyl and butyl 4-hydroxybenzoates.
[0089] The compositions of the invention may be produced by
conventional pharmaceutical techniques. Thus the aforementioned
compositions, for example, may conveniently be prepared by mixing
together at an elevated temperature, preferably 60-70.degree. C.,
the soft paraffin, liquid paraffin if present, and lanolin or
derivative or synthetic equivalent thereof. The mixture may then be
cooled to room temperature, and, after addition of the hydrated
crystalline calcium salt of mupirocin, together with the
corticosteroid and any other ingredients, stirred to ensure
adequate dispersion.
[0090] Regardless of the manner of administration, the specific
dose is calculated according to the approximate body weight of the
host. Further refinement of the calculations necessary to determine
the appropriate dosage for treatment involving each of the above
mentioned formulations is routinely made by those of ordinary skill
in the art and is within the scope of tasks routinely performed by
them without undue experimentation, especially in light of the
dosage information and assays disclosed herein. These dosages may
be ascertained through use of the established assays for
determining dosages utilized in conjunction with appropriate
dose-response data.
[0091] It should be noted that the invention described herein may
be used for veterinary as well as human applications and that the
term "host" should not be construed in a limiting manner. In the
case of veterinary applications, the dosage ranges can be
determined as described above, taking into account the body weight
of the animal.
EXAMPLES
[0092] The following examples are provided for illustrative
purposes only and are not intended to limit the scope of the
invention.
Example 1. Method for the Quantification of Bakuchiol, Psoralen and
Isopsoralen by HPLC
[0093] The amount of bakuchiol, psoralen and isopsoralen in the
extracts, fractions, and the novel composition generated as
described below was quantified by a high pressure liquid
chromatography (HPLC) using a PhotoDiode Array detector (HPLC/PDA)
and a Luna Phenyl-hexyl column (250 mm.times.4.6 mm). The targeted
compounds were eluted from the column using an acetonitrile (ACN)
water gradient from 36% to 100% ACN over a period of 12 minutes,
followed by 100% ACN for three minutes. The detailed HPLC
conditions used are set forth in Table 1. A chromatogram of the
HPLC separation is depicted in FIG. 1. The targeted compounds wore
identified and quantified based on retention time and UV peak area
using commercially available pure bakuchiol, psoralen and
isopsoralen as quantification standards. The retention times for
the bakuchiol, psoralen and isopsoralen were 18.19 minutes, 7.33
minutes and 7.95 minutes, respectively.
TABLE-US-00002 TABLE 1 HPLC Conditions for quantification of
Bakuchiol, Psoralen and Isopsoralen Column Luna Phenyl-hexyl, 150
.times. 4.6 mm Gradient 0-8 min 36% ACN/water 8-20 min 36%
ACN/water to 100% ACN 20-23 min 100% ACN 23-28 min 36% ACN/water
Flow rate 1 mL/min Detection 0-11 min 246 nm (for psoralen and
angelicin, 7-8 min) 11-28 min 260 nm (for bakuchiol, 18-19 min)
Temperature 35.degree. C. Standard concentration 0.1 mg/mL in MeOH
for bakuchiol 0.025 mg/mL for psoralen and angelicin Extract
preparation 0.2 mg/mL in MeOH Linear range 0.01 mg/mL to 0.15
mg/mL
Example 2. General Methods for the Extraction of Bakuchiol from
Psoralea Plants
Wrist Shaker
[0094] To a flask was added solvent (100 mL) and Psoralea
corylifolia seed powder (10 g) and the mixture was shaken on a
waist shaker at room temperature for one hour. The mixture was then
passed through a filter and the filtrate collected. The extraction
process was repeated one more time with fresh solvent, the
filtrates were combined, the solvent removed on a rotoevaporator
and the residue was dried under high vacuum.
Reflux
[0095] To a flask was added solvent (50 mL) and Psoralea
corylifolia seed powder (10 g) and the mixture was refluxed for 40
min. The solution was then filtered and the extraction process was
repeated two more times with fresh solvent. The filtrates were
combined and the solvent was evaporated to obtain a dried
extract.
[0096] Following above extraction methods, sample plant material
was extracted with the following solvents: dichloromethane (DCM),
EtOAc, acetone, MeOH, petroleum ether (BP 35-60.degree. C.) and
petroleum ether (BP 60-90.degree. C.). The extracts were then
analyzed by HPLC analysis as described in Example 1. The results
are set forth in Table 2.
TABLE-US-00003 TABLE 2 Quantification of various Psoralea
corylifolia extracts Petroleum Petroleum Petroleum Ether Ether
Ether (35-60.degree. C.) DCM EtOAc Acetone MeOH (35-60.degree. C.)
(60-90.degree. C.) Extract wt. (g) 0.5833 1.7535 1.6710 1.8932
1.8795 0.6457 0.9203 % Bakuchiol 29.1% 14.2% 13.7% 13.7% 13.9%
25.6% 27.2% in Extract % Bakuchiol 1.7% 2.5% 2.3% 2.6% 2.6% 2.6%
2.7% in Plant Method Wrist shaker (100 ml/10 g solid) Reflux (50
ml/10 g solid)
Example 3. Large Scale Extraction of Bakuchiol from Psoralea
Plants
[0097] Seed powder of Psoralea corylifolia (2 kg) and 9 liter of
petroleum (pet.) ether (BP 60-90.degree. C.) were rotated in a 20 L
flask on a rotoevaporator at 70.degree. C. in a water bath for 1
hour. The solution was then decanted into a separate container and
the solvent was removed under vacuum. Fresh solvent was added into
the biomass and the extraction process was repeated three more
times. The extracts were combined and evaporated to yield 335 g of
a crude extract (MH-258-01-01) having 21% bakuchiol and 3%
psoralen/isopsoralen by weight.
Example 4. Evaluation of Various Chromatographic Methods for
Purifying Bakuchiol Extracts
[0098] Various chromatographic methods for purifying the crude
solvent extract (MH-206-70-1) isolated from the seeds of Psoralea
corylifolia using the method described in Example 2, were evaluated
to determine the potential for using column chromatography as a
means of obtaining high purity bakuchiol free of contamination by
furanocoumarins, particularly psoralen/isopsoralen contamination.
Briefly, each empty column cartridge (1.3 cm ID and 20 mL capacity,
from Bio-Rad) was packed with a different and eluted with different
solvents in an attempt to separate the furanocoumarin impurities
from bakuchiol. The fractions (10 mL per fraction) were collected
in test tubes and analyzed with silica gel TLC plates developing
with 20% EtOAc/petroleum ether. The targeted compounds, bakuchiol,
psoralen and isopsoralen were identified based on their retention
times, which were determined using standard solutions. The results
are set forth in Table 3.
TABLE-US-00004 TABLE 3 Summary of column chromatographic separation
of bakuchiol from furanocoumarins in crude extracts of Psoralea
corylifolia Column size/ Media Extract Loading Elution Solvent
Results Al.sub.2O.sub.3 (neutral) 2 mL/25 mg 1. petroleum ether
Little separation (J. T. Baker) 2. EtOAc 3. MeOH XAD-4 (amerlite 5
mL/19 mg MeOH/water gradient in No separation polystyrene 20%
increments from 100% resin) water to 100% MeOH XAD-7 (amerlite 8
mL/16 mg pet. ether/EtOAc gradient in Some separation polyacrylate
20% increments from 100% resin) petroleum ether to 100% MeOH
MeOH/water gradient in Little separation 20% increments from 100%
water to 100% MeOH Polyamide 5 mL/50 mg 1. petroleum ether No
separation 2. 5% acetone/pet. ether 3. acetone LH-20 8 mL/50 mg
petroleum ether No separation Silica gel 5 mL/50 mg 1. petroleum
ether Good separation 2. 15% EtOAc/pet. ether CG-71md 5 mL/50 mg 1.
petroleum ether No separation 2. acetone CG-161cd 5 mL/50 mg
petroleum ether No separation 6 mL/50 mg MeOH/water step gradient
Good separation Low yield
Example 5. Hydrolysis of a Petroleum Ether Extract Isolated from
the Seeds of Psoralea corylifolia
[0099] A petroleum ether extract (25 g; MH-258-01-01), isolated
from the seeds of Psoralea corylifolia as described in Example 3,
was mixed with 500 mL of a NaOH solution (56.5 mM) in a 1 L round
bottom flask. The solution was refluxed in a heating mantel for one
hour. A small portion of the solution was taken from the flask
periodically and analyzed by HPLC as described in Example 1. The
reaction was stopped after HPLC analysis showed that the peaks for
psoralen and isopsoralen had completely disappeared. The reaction
mixture was then cooled to room temperature to yield a dark brown
solution having a solid content of approximately 36 mg/mL
(MH-258-10-01).
[0100] To 20 mL of the hydrolysis solution (MH-258-10-01) in a
separatory funnel (150 mL) was added DCM (20 mL). The mixture was
shaken for 10 min and the layers were allowed to separate. The DCM
layer was removed from the bottom of the separatory funnel and the
extraction was repeated one more time with 20 mL of fresh DCM. The
organic layers were combined, and the solvent removed by rotary
evaporation under vacuum to yield 118 mg of a composition
(MH-258-07-01), which contained 31% bakuchiol and was free of
furanocoumarin contaminants (FIG. 3).
[0101] To 20 mL of the hydrolysis solution (MH-258-10-01) in a
separatory funnel (150 mL) was added petroleum ether (20 mL). The
mixture was shaken for 10 min. and the layers were allowed to
separate. The petroleum ether layer was removed from the top of the
separatory funnel and the extraction was repeated one more time
with 20 mL of fresh petroleum ether. The organic layers were
combined and the solvent removed by rotary evaporation under vacuum
to yield 136 mg of a composition (MH-258-07-02), which contained
41% bakuchiol and was free of furanocoumarin contaminants (FIG.
4).
Example 6. Hydrolysis of a Methanol Extract Isolated from the Seeds
of Psoralea corylifolia
[0102] A dried methanol extract (MH-293-68-Q1), isolated from the
seeds of Psoralea corylifolia as described in Example 2, was mixed
with 1 L of a NaOH solution (44 g NaOH in DI water) in a 2 L beaker
on a stirrer/hot plate. The solution was stirred while boiling for
2 hours, Water was added to the beaker as necessary to maintain the
total volume at about 1200 mL. After 2 hours the solution was
allowed to cool to room temperature, after which time 600 mL was
transferred to a separatory funnel. Petroleum ether (250 mL) was
added and the mixture was shaken for 10 min. and the layers were
allowed to separate. The petroleum ether layer was removed from the
top of the separatory funnel and the extraction was repeated
(3.times.) with fresh solvent. The organic extracts were combined
and the solvent removed by rotary evaporation under vacuum to yield
2.25 g of a composition (MH-293-74-01), which contained 51%
bakuchiol and was free of furanocoumarin contaminants.
Example 7. Hydrolysis of Petroleum Ether Extract Isolated from the
Seeds of Psoralea corylifolia Followed by Purification by Column
Chromatography
[0103] A petroleum ether extract (25 g; MH-258-G1-01), isolated
from the seeds of Psoralea corylifolia as described in Example 3,
was mixed with 500 mL of a NaOH solution (56.5 mM) in a 1 L round
bottom flask. The solution was refluxed for one hour. A small
portion of the solution was taken from the flask periodically and
analyzed by HPLC as described in Example 1. The reaction was
allowed to proceed until HPLC analysis showed that the peaks for
psoralen and isopsoralen had completely disappeared. The reaction
mixture was then cooled to room temperature to yield a dark brown
solution having a solid content of approximately 36 mg/mL
(MH-258-10-01).
[0104] 150 mL of this solution (MH-258-10-01) was loaded onto a
pre-prepared CG-161cd column. The pre-prepared column (5.times.13
cm) contained 300 mL of CG-161cd resin, which had been equilibrated
with 4 column volumes of DI water. The loading material
(MH-258-10-01) was fed into the top of the column and eluted with
2500 mL of DI water to bring the column to pH 7, followed by 2500
mL of 70% MeOH/water and 4500 mL of 90% MeOH/water to elute
bakuchiol. The eluent was monitored by TLC until the bakuchiol was
completely eluted from the column. Fractions containing only
bakuchiol (2 L) were combined and evaporated under vacuum to remove
the solvent. Using this method highly pure bakuchiol (2.3 g) (99%
pure, MH-258-12-08 and -09), free of furanocoumarin contamination
was obtained. (See FIG. 5). Earlier and later bakuchiol fractions
were also collected, combined and evaporated under vacuum. From
these fractions a composition (MH-258-12-07 and -10) was obtained
in a quantity of 2.4 grams, which contained 70% bakuchiol free of
furanocoumarin contamination. The loading capacity of the CG-161cd
column was estimated as 400 mL of the crude hydrolysis solution per
liter of CG-161 cd resin. After separation, the CG-161cd column was
recovered by washing with Clorox followed with MeOH and 4 column
volumes of DI water. It can be reused for a number of years.
Example 8. Inhibition of COX-1 and COX-2 by Purified Bakuchiol
[0105] In order to screen for compounds that inhibited COX-1 and
COX-2 activity, a high throughput, in vitro assay was developed
that utilized the inhibition of the peroxidase activity of both
enzymes. (Needleman et al. (1986) Anna Rev Biochem. 55:69).
Briefly, the composition or compound being examined was titrated
against a fixed amount of COX-1 and COX-2 enzymes. A cleavable,
peroxide chromophore was included in the assay to visualize the
peroxidase activity of each enzyme in presence of arachidonic acid
as a cofactor. Typically, assays were performed in a 96-well
format. Each inhibitor, taken from a 10 mg/mL stock solution in
100% DMSO, was tested in triplicate at room temperature using the
following range of concentrations: 0, 0.1, 1, 5, 10, 20, 50, 100,
and 500 .mu.g/mL. To each well, 150 .mu.L of 100 mM Tris-HCl, pH
7.5 was added along with 10 .mu.L of 22 .mu.M Hematin diluted in
tris buffer, 10 .mu.L of inhibitor diluted in DMSO and 25 units of
either the COX-1 or COX-2 enzyme. The components were mixed for 10
seconds on a rotating platform, followed by the addition of 20
.mu.L of 2 mM N,N,N'N'-tetramethyl-p-phenylenediamine
dihydrochloride (TMPD) and 20 .mu.L of 1.1 mM arachidonic acid to
initiate the reaction. The plate was shaken for 10 seconds and then
incubated 5 minutes before reading the absorbance at 570 nm. The
inhibitor concentration vs. % inhibition was plotted and the
IC.sub.50 determined by taking the half-maximal point along the
isotherm and intersecting the concentration on the X-axis. The
IC.sub.50 was then normalized to the number of enzyme units in the
assay. A high purity (99%) bakuchiol sample (MH-258-08 was tested
for both COX-1 and COX-2 inhibition. The results are summarized in
the following Table 4.
TABLE-US-00005 TABLE 4 Inhibition of COX activity by bakuchiol
Compound Name COX-1 (IC.sub.50) COX-2 (IC.sub.50) MH-258-08 2.34
.mu.M 5.78 .mu.M (99% bakuchiol)
Example 9. Inhibition of 5-Lipoxygenase by Purified Bakuchiol
(MH258-12-08)
[0106] As noted above, one of the most important pathways involved
in the inflammatory response is produced by non-heme,
iron-containing lipoxygenases (5-LOX, 12-LOX, and 15-LOX), which
catalyze the oxidation of fatty acids such as AA to produce the
hydroperoxides 5-, 12- and 15-HPETE, which are then converted to
leukotrienes, A Lipoxygenase Inhibition Assay was carried out using
a published method (Carter et al. (1991) J. Pharmacol. Exp. Ther.
256(3):929-937, Safayhi et al. (2000) Planta Medica, 66:110-113).
5-LOX was isolated from human PBML cells and arachidonic acid was
utilized as a substrate. The test article and positive control were
dissolved in 1% DMSO. HESS (Hank's balanced salt solution) was used
as incubation buffer. Pre-incubation time was 15 minutes at
37.degree. C., followed by 15 min. incubation at the same
temperature. This assay detects the formation of LTB4 with EIA
quantification. Highly pure bakuchiol (99% bakuchiol,
#MH-258-12-08) was tested in duplicate at concentrations of 10
.mu.M, 1 .mu.M, 0.1 .mu.M, and 10 nM relative to a positive
control--NDGA at five concentrations. The dose response curve is
illustrated in the FIG. 6. The IC.sub.50 for 5-LOX inhibition by
bakuchiol (99% pure) was 3.41 .mu.M.
Example 10. Antimicrobial Activity of Purified Bakuchiol
[0107] The anti-microbial activity of a highly pure bakuchiol
sample (99% pure; #MH-258-12-08) was evaluated using published
methods (Modugno et al. (1994) Antimicrobial Agents &
Chemotherapy 38:2362-2368; Misiek el al. (1973) Antimicrobial
Agents & Chemotherapy 3:40-48). Briefly, Staphylococcus
epidermidis (Gram Positive, ATCC 12228) was cultured for 20 hours
at 37.degree. C. in Mueller-Hinton Broth medium. Propionibacterium
acnes (ATCC 6919) was cultured for 2 days at 37.degree. C. in
Reinforced Clostridial medium. The test article and positive
control were dissolved in 1% DMSO with an incubation volume of 1
mL. The time of assessment was 1 day. Measurement of turbidity was
used as the method of quantification. A highly pure bakuchiol
sample (99%; #MH-258-12-08) was tested in duplicate at
concentrations of 100 .mu.g/mL, 30 .mu.g/mL, 10 .mu.g/mL, 3
.mu.g/mL, 1 .mu.g/mL, 0.3 .mu.g/mL, 0.1 .mu.g/mL and 0.03 .mu.g/mL
relative to positive controls-gentamicin at 0.1 .mu.g/mL for
Staphylococcus epidermidis and ampicillin at 0.1 .mu.g/mL for
Propionibacterium acnes, respectively. Significant inhibition was
exhibited by bakuchiol at 1 .mu.g/ml against both Staphylococcus
epidermidis and Propionibacterium acnes. The highly pure sample of
bakuchiol also inhibited the activity of Trichophyton
rnentagrophytes (ATCC 9533) at a moderate concentration of 30
.mu.g/mL. Finally, no inhibition was observed for Epidermophyton
floccosum (ATCC 18397), Microsporum canis (ATCC 36299) and
Pityrosporum ovale (ATCC 38593).
Example 11. Evaluation of Acute Toxicity of Purified Bakuchiol
[0108] Acute Toxicity studies were completed testing two purity
levels of bakuchiol (UP256) (a sample that was approximately 20%
pure and a sample which was 99% pure). Forty female ICR mice
(Harlan) aged 4-5 weeks old were used for the 14-day study. Mice
were administered 100 mL of the acute dose daily, approximately 2
g/kg by weight per test article per day. The first 10 mice received
the composition containing 20.7% bakuchiol, while the second group
of 10 mice received a composition containing 99% bakuchiol. The
UP256 composition was suspended in water and administered through a
syringe. Twenty mice were administered water, as the control group.
The weights of all mice were measured, including baseline, 3 mid
points, and an endpoint. Also, food and water consumption were
observed for all groups. Any abnormal health conditions or behavior
was recorded over the two-week period. A necropsy of all mice was
completed on day 14 and blood from all groups was collected for a
complete blood screen. Two mice picked randomly from each of groups
also had kidney and liver tissues removed for Histopathology. All
blood work and pathology work was completed through Antech
Diagnostics.
[0109] The average weight calculated for all groups, including
controls, continued to increase over the two-week study period. No
mouse showed a decrease in weight, and food/water consumption
remained the same for all groups. Aggression towards the
investigator (i.e. biting) and towards each other (i.e. fighting in
cage) was the only significant difference in behavior among the
treated mice compared to the control mice. This is a behavior that
would be expected in the mice receiving androgen, a male hormone.
The necropsy of all mice showed no gross abnormalities or changes
in any organ. The blood work showed the treated groups were normal
relative to the controls. The protein, enzyme, and ion levels were
within normal values for ICR mice. The kidney and liver tissues
were sent for Histopathology to assess any micro changes in the
organs and the report stated that significant changes were not
present in the kidney and the hepatocyte nuclei for the liver were
within normal limits for mice. There was no substantial
inflammation or evidence of neoplasia in either tissue section
examined.
[0110] In conclusion, all weights, blood work, and histological
data, was the same for the treated mice relative to the control
group. No adverse effects were observed in the fourteen-day study
for either sample of UP256. Therefore, it can be concluded that
UP256 at both purity levels (20% and 99% purity) has a solid safety
profile
* * * * *